Home health remedies Teva scouts new CFO as McClellan steps down for personal reasons

Teva scouts new CFO as McClellan steps down for personal reasons

38
0
SHARE

Teva CEO Kåre Schultz has spent nearly two years working through major issues at the generics giant. Now, he’ll need to replace his CFO, as Michael McClellan is stepping down. 

McClellan is resigning for personal reasons to be closer to his family, Teva said Wednesday.  He’s expected to stay with the company through third-quarter earnings to ensure a smooth transition, but meanwhile, the company is searching for its next CFO.  

The outgoing finance chief has served in the role since November 2017, when Schultz promoted him from an interim post he assumed in the wake of longtime CFO Eyal Desheh’s exit. That year, before McClellan officially took over, Teva cut its guidance three timestwice by more than $1 billion.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Before that, McClellan served as the SVP and CFO of the company’s global specialty medicines outfit for two years. Earlier in his career, he spent nearly 20 years at Sanofi, working up to the role of U.S. CFO. 

RELATED: Teva, amid massive restructuring, closes in on $3B cost-cutting goal 

In Wednesday’s announcement, Schultz took a chance to thank McClellan, who helped preside over Teva’s $3 billion cost-cutting drive, for his service during “such challenging times.” For his part, McClellan said he’s “confident that Teva has the financial strength and capabilities to ensure its growth and success.” 

Teva’s new CFO will be coming in to help manage a challenged business. For years, the company has been cutting costs to deal with generic pricing struggles in the U.S. and generics to its multiple sclerosis med Copaxone. Things looked slightly better on Wednesday, when the drugmaker reported earnings better than analysts had expected. 

In the second quarter, Teva posted revenues of $4.3 billion, beating consensus estimates by $90 million. Earnings per share of 60 cents also bested analyst estimates of 55 cents. Back in May, the company reported it was nearing its $3 billion cost-cutting goal. 

RELATED: A $10B settlement? Or $45B? Distributors, AGs go back and forth in opioid talks: Bloomberg 

Teva’s stock has been hovering at or around 20-year lows amid all of its issues, including opioid litigation. The drugmaker is one of several involved in nationwide opioid litigation, and it has already agreed to an $85 million settlement in Oklahoma.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

eighteen − 17 =